Yes, Sublocade is a Schedule III controlled substance under the federal Controlled Substances Act. This means it has an accepted medical use but also carries some potential for abuse and dependence, though less so than drugs in Schedules I or II (like heroin or oxycodone). The Schedule III classification applies to all buprenorphine products, including Sublocade.
What Schedule III Means in Practice
The DEA organizes controlled substances into five schedules based on their potential for misuse and whether they have legitimate medical applications. Schedule III sits in the middle: these drugs have a moderate-to-low potential for physical and psychological dependence. Other Schedule III substances include certain testosterone preparations and ketamine.
For patients, this classification mostly affects how the medication is handled behind the scenes. Healthcare facilities must store Schedule III drugs in a securely locked, substantially constructed cabinet. Any theft or significant loss must be reported to the DEA within one business day, and staff with felony drug convictions cannot have access to the medication. These requirements exist to prevent diversion, which is the term for controlled substances ending up in the wrong hands.
Why Buprenorphine Is Controlled
Sublocade’s active ingredient is buprenorphine, a partial opioid agonist. It activates the same brain receptors as stronger opioids like morphine or fentanyl, but only partially. Think of it like a key that fits the lock but only turns halfway. This partial activation produces a “ceiling effect,” meaning that after a certain dose, taking more doesn’t increase sedation or the dangerous slowing of breathing that full opioids cause.
That ceiling effect is exactly why buprenorphine is placed in Schedule III rather than Schedule II. It can still produce mild euphoria and physical dependence, which justifies controlled substance status, but its abuse potential is substantially lower than full opioid agonists.
How Sublocade Differs From Other Buprenorphine Products
While daily buprenorphine tablets or films dissolve under the tongue, Sublocade is a once-monthly injection given just under the skin of the abdomen. It comes in two strengths: 100 mg and 300 mg. The standard approach is two initial 300 mg injections followed by monthly 100 mg maintenance doses, with each injection spaced at least 26 days apart.
The injection forms a small solid deposit under the skin that slowly releases buprenorphine over the course of the month. This design largely eliminates the daily decision to take medication and removes the possibility of a patient diverting take-home doses, which is one reason Sublocade has a unique safety profile compared to sublingual buprenorphine.
The REMS Restriction
Sublocade carries an additional layer of restriction beyond its Schedule III classification. The FDA requires it to be distributed through a Risk Evaluation and Mitigation Strategy (REMS) program, which is reserved for medications with serious safety concerns that need extra safeguards.
The specific risk driving the REMS is intravenous misuse. If Sublocade’s formulation enters the bloodstream directly, it forms a solid mass on contact with body fluids. This can block blood vessels, damage tissue, and cause life-threatening blood clots, including pulmonary emboli. The FDA’s black box warning, the most serious warning a drug can carry, explicitly states that serious harm or death could result from intravenous administration.
Because of this, you cannot pick up Sublocade at a pharmacy and take it home. Certified healthcare settings and pharmacies order the medication and dispense it directly to a healthcare provider, who then administers the injection on-site. Patients never handle the drug themselves.
How Prescribing Rules Have Changed
Until recently, clinicians needed a special federal waiver (commonly called the “X-waiver”) to prescribe any buprenorphine product for opioid use disorder. The Consolidated Appropriations Act of 2023 eliminated that requirement entirely. Now, any practitioner with an active DEA registration that includes Schedule III prescribing authority can prescribe buprenorphine for opioid use disorder, as long as their state law allows it.
The law did add one new requirement: clinicians applying for a new DEA registration or renewing an existing one must complete at least eight hours of training on substance use disorders, hold board certification in addiction medicine or addiction psychiatry, or have graduated within five years from a program that included at least eight hours of substance use disorder coursework. This change was designed to expand the number of providers who can offer buprenorphine treatment while ensuring a baseline level of training.
Sublocade is specifically FDA-approved for moderate to severe opioid use disorder in patients who have already started on a sublingual buprenorphine product and stabilized on it for at least seven days. It is not a first-line standalone treatment; the stabilization period on daily buprenorphine comes first.